{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "NRIX", "name": "Nurix Therapeutics, Inc.", "url": "https://orbyd.app/dossiers/NRIX/", "json_url": "https://orbyd.app/dossiers/NRIX.json", "status": "DORMANT", "current_conviction": "MEDIUM", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Roche co-development deal (2026-07-21: $700M upfront, up to $2.3B, 60/40 cost-share) just gave Big Pharma validation to the bexobrutideg BTK-degrader franchise the sell-side re-rated in July, re-accelerating the narrative. But no dated clinical catalyst until ASH ~December and the tape is overbought post-deal, so the read favors a base-retest over a post-gap chase.", "invalidation_trigger": "A weekly close below $24 surrenders the post-Roche re-rating and breaks the June breakout base that carried the July target cluster; secondary: a bexobrutideg CLL durability disappointment at the ~December ASH readout, or the degrader theme flipping to SATURATED on retail pile-in.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "oncology-immunology" ], "tags": [], "sources": [], "notes": [ "No confirmed dated catalyst within 30 days as of 2026-07-11; next heavyweight readout likely ASH 2026 (~December).", "Sell-side is clustered bullish (nine Buy/Outperform actions 06-15 to 07-10, PTs $32-40) — treat further target raises as late confirmation, not fresh signal.", "Overbought flag 2026-06-30; prefer retest entries toward the June breakout base over chasing the post-print gap.", "Collaboration/milestone revenue is lumpy; a quarterly 'sales miss' (Q2 2026-07-09: $9.043M vs $16.170M consensus, a 44% shortfall) is largely partner-timing noise — the value driver is bexobrutideg CLL clinical data.", "Roche co-development finalized 2026-07-21: $700M upfront, up to $2.3B with milestones, 60/40 cost-share (Roche 60% / Nurix 40% of bexobrutideg clinical dev costs) — de-risks burn and validates the asset with a Big Pharma partner.", "No dated clinical catalyst within 30 days as of 2026-07-26; next heavyweight readout is bexobrutideg CLL durability at ASH ~December 2026.", "Sell-side clustered bullish (targets $31–40 from 2026-06-15 to 2026-07-22: Stifel $40, HC Wainwright/Truist/Needham/Mizuho $34, RBC/Baird $33, BTIG $32, UBS $31); treat further target raises as late confirmation, not fresh signal.", "Overbought flag 2026-06-30 (NRIX/DFTX/GALT RSI screen); extended into a catalyst vacuum — prefer a base-retest toward the June breakout base (low-$20s) over chasing post-deal gaps." ], "body_markdown": "## Current Thesis\n\nNurix is a targeted-protein-degradation biotech whose value concentrates in one asset, bexobrutideg (NX-5948), an oral BTK degrader in relapsed/refractory CLL. The narrative leg on offer changed character on 2026-07-21, when Roche finalized a co-development collaboration on bexobrutideg: $700M upfront, up to $2.3B with milestones, and a 60/40 clinical-cost split with Roche carrying the larger share. That is Big Pharma underwriting the same franchise the sell-side re-rated two weeks earlier, and it arrives as balance-sheet cash and external validation on top of the July target cluster. The offset is timing: the stock was flagged overbought on 2026-06-30, the Roche print re-rated it again, and the next hard clinical catalyst — CLL durability data at ASH ~December — sits months out. The story is accelerating; the entry is extended.\n\n## Bull Case\n\n- **Roche puts $700M on the table for bexobrutideg (2026-07-21).** Upfront of $700M, up to $2.3B including milestones, with Roche carrying 60% of clinical development costs against Nurix's 40%. For a clinical biotech that missed Q2 revenue, that is a non-dilutive runway extension and the most credible third-party endorsement the asset could get.\n- **Sell-side already re-rated the franchise (2026-07-10).** Six firms stacked targets $32–40 the day after the Q2 miss — Stifel $40, HC Wainwright $34, Truist $34, Needham $34, RBC $33, BTIG $32 — with Baird at $33 on 2026-06-18. Post-deal, Mizuho stepped to $34 (2026-07-13) and UBS reiterated Buy at $31 (2026-07-22).\n- **Degradation sidesteps BTK resistance (EHA preview, 2026-06-11).** The EHA 2026 preview cited durable responses in CLL patients who progressed on covalent and non-covalent BTK inhibitors and BCL2 inhibitors — degrading BTK rather than inhibiting it avoids the C481S/L528W mutations that break pirtobrutinib.\n- **Platform still funded by multiple partners.** Gilead, Sanofi and Pfizer collaborations underwrite the DELigase degrader engine and carry their own milestone optionality, now sitting on top of the Roche bexobrutideg economics.\n\n## Bear Case\n\n- **The entry is late and extended.** The 2026-06-30 overbought flag (NRIX alongside DFTX and GALT) preceded the July target cluster and the Roche gap. Buying after a $700M deal has already printed is buying the reaction, and small-cap biotech gaps mean-revert hard when the news flow pauses.\n- **No dated near-term catalyst.** The Roche deal is done; the Q2 print is behind. The next heavyweight clinical readout is ASH ~December, leaving weeks of catalyst vacuum in which a re-rated, overbought name can drift.\n- **Clinical-stage binary risk remains.** Bexobrutideg's registration path, durability curve and safety profile are unproven at scale. A soft update at the ASH readout can gap the stock 20–40% regardless of the Roche endorsement.\n- **Q2 revenue miss was large (2026-07-09).** Sales $9.043M vs $16.170M consensus is a 44% shortfall; EPS $(0.81) missed $(0.74). Collaboration revenue is lumpy, but a gap that size keeps burn and partner-timing risk on the table.\n- **Competition targets the same niche.** BeiGene's BGB-16673 and other BTK degraders are chasing the same resistant-CLL population; a superior competitor readout re-rates Nurix down.\n\n## Setup & Price Structure\n\nThe modality theme reads accelerating and the analyst tape is one-sided — nine-plus Buy/Outperform actions from 2026-06-15 through 2026-07-22, targets clustering $31–40. The Roche deal on 2026-07-21 is a genuine new leg, which distinguishes this refresh from the mid-July setup where analysts were arriving after the move. Structurally the name broke out of a low-$20s base in June, ran into the 2026-06-30 overbought screen, gapped on the July target cluster, then gapped again on the Roche print. Support that matters sits at the June breakout base in the low-$20s; that shelf held through two positive catalysts and is where a failed re-rate would show up first. The tension for a fresh entry is stretch — a name this extended into a catalyst vacuum tends to offer a cleaner base-retest than a post-gap chase.\n\n## Catalyst Calendar (next 30 days)\n\n- **ASH 2026 (~2026-12, est.).** The next heavyweight bexobrutideg CLL durability readout and the true clinical binary, outside this 30-day window.\n- **Roche deal-mechanics filings (est. weeks ahead).** An 8-K or updated cash/runway disclosure detailing the $700M and cost-share terms could land in the coming weeks and reset the burn model.\n\n## Elapsed catalysts\n\n- **No dated binary within 30 days.** The Roche collaboration closed 2026-07-21; the Q2 report is behind (2026-07-09). *(passed 19d ago)*\n- **Ongoing sell-side actions.** Target revisions keep trickling (UBS $31, 2026-07-22; Mizuho $34, 2026-07-13) — treat further raises as late confirmation of a franchise already re-rated, not fresh signal. *(passed 18d ago)*\n\n## What Would Change Our Mind\n\nThe bull read weakens on a weekly close below $24, which surrenders the post-Roche re-rating and breaks the June breakout base that carried the July target cluster. A bexobrutideg CLL durability disappointment at the ASH readout would break the clinical spine of the thesis independent of price. The degrader modality flipping to SATURATED on mainstream/retail pile-in — or a competing BTK-degrader readout (BeiGene BGB-16673) reading cleaner on the same resistant-CLL population — would remove the first-to-category premium. And a repeat quarterly revenue miss, now that Roche cost-share should smooth the collaboration line, would point at something worse than lumpy partner timing.\n\n## Correlation Notes\n\nNurix trades as a targeted-protein-degradation and small/mid-cap oncology name — beta to XBI and clinical-biotech risk appetite dominates its moves outside catalyst windows. It correlates with BTK-degrader peers (BeiGene's BGB-16673 program) and, on the platform side, with sentiment toward its named partners Gilead, Sanofi, Pfizer and now Roche. It is rate-sensitive: long-duration clinical biotech de-rates when real yields rise. Deal read-through cuts both ways — a further Big Pharma degrader partnership across the group validates the modality, while a high-profile degrader clinical failure anywhere re-prices the whole cohort.", "first_seen": "2026-07-07", "last_analyzed": "2026-07-26T12:33:58+00:00", "last_synthesized": "2026-07-26", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }